Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Silexion’s filings can feel like decoding lab notes. Clinical data tables, RNA interference protocols, and financing footnotes sprawl across hundreds of pages, yet every detail may move the stock before the next trial read-out. If you have ever typed “Silexion SEC filings explained simply” or wondered whether the latest 8-K covered new KRAS results, you are not alone.
Stock Titan solves that problem. Our AI instantly converts dense disclosures into clear takeaways—highlighting cash runway, trial milestones, and partnership clauses—so you can focus on decisions, not document searches. Need to monitor “Silexion insider trading Form 4 transactions” or get a “Silexion quarterly earnings report 10-Q filing” the moment it hits EDGAR? We deliver real-time alerts and plain-English summaries, all in one place.
Here is what you will find on this page:
- “Silexion annual report 10-K simplified” to spot R&D spend and dilution risk.
- “Silexion Form 4 insider transactions real-time” tracking executive sentiment and option exercises.
- “Silexion proxy statement executive compensation” showing how management is rewarded for RNAi milestones.
- “Silexion 8-K material events explained” including clinical data releases or new Evonik agreements.
- “Silexion earnings report filing analysis” with AI-flagged shifts in trial timelines.
From “understanding Silexion SEC documents with AI” to catching a sudden “Silexion executive stock transactions Form 4,” every filing type is covered—10-K, 10-Q, 8-K, S-1, DEF 14A, and more—updated the second EDGAR posts. Spend less time untangling scientific jargon and more time evaluating whether SIL-204’s next data drop aligns with your investment thesis.
Orca Capital AG reported beneficial ownership of 109,432 ordinary shares of Silexion Therapeutics Corp, representing 4.9% of the outstanding class based on 2,123,892 shares outstanding after the issuer's registered offering. The filing clarifies that the reporting person also holds warrants for 153,068 ordinary shares but cannot exercise them to the extent doing so would increase beneficial ownership above 4.99% (the "4.99% Blocker"). Orca states the securities were not acquired to change or influence control of the issuer and reports sole voting and dispositive power over the reported shares.
Orca Capital AG disclosed ownership of 131,250 ordinary shares of Silexion Therapeutics Corp (CUSIP G1281K130), representing 6.2% of the outstanding class based on 2,123,892 shares after the issuer's registered offering. Orca reports sole voting and dispositive power over these shares. The filing notes Orca holds warrants for 262,500 additional shares but cannot exercise them to the extent doing so would increase its stake above a 4.99% blocker under the warrant terms. The statement affirms the position was not acquired to change or influence control of the issuer.
Lincoln Alternative Strategies LLC reported beneficial ownership of 131,250 ordinary shares of Silexion Therapeutics Corp., representing 6.18% of the outstanding common stock based on 2,123,892 shares outstanding as of September 12, 2025. The filing on Schedule 13G states the shares are held with sole voting and dispositive power and that they were not acquired to change or influence control of the issuer. The report lists the filers Delaware organization, principal address in Miami Beach, FL, and is signed by Stephen Temes as Managing Member on September 15, 2025.
Silexion Therapeutics Corp filed an S-1 registration for an offering of ordinary shares, pre-funded warrants and ordinary warrants under Nasdaq tickers SLXN and SLXNW. The company is a development-stage RNAi therapeutics firm focused on KRAS-silencing candidates, including first-generation siG12D-LODER (Phase 1/2 data showing a numerical OS advantage in KRAS G12D/V patients) and second-generation SIL204 (preclinical stability, PK and in vivo efficacy data).
Financially, Silexion reported net losses of $16.5 million for 2024 (vs. $5.1 million in 2023) and had $3.5 million in cash as of June 30, 2025. Management states there is substantial doubt about the companys ability to continue as a going concern without additional financing. The S-1 discloses potential dilution from existing warrants, a $3.433 million promissory note convertible into shares, and an equity line (White Lion) that could issue up to $11.9 million of shares.
Silexion Therapeutics Corp (SLXN) filed an S-1 registering resale of up to 314,859 ordinary shares issuable upon exercise of warrants and discloses recent financings, operational results and liquidity constraints. For the six months ended June 30, 2025 the company reported a net loss of $4.238 million and cash and cash equivalents of $3.466 million. For the year ended December 31, 2024 net loss was $16.519 million, driven by higher R&D, G&A and financings costs. The company completed a public offering in January 2025 that generated approximately $5.0 million gross and subsequent warrant inducement transactions produced additional proceeds. Management notes substantial doubt about the company’s ability to continue as a going concern and disclosed Nasdaq listing compliance actions and two reverse share splits in 2024 and 2025.
Silexion Therapeutics Corp filed a Form S-8 to register up to 84,791 ordinary shares issuable under the Silexion Therapeutics Corp 2024 Equity Incentive Plan. The additional share allocation was approved by the board and by shareholders at the 2025 annual general meeting held July 14, 2025. The filing incorporates prior Form S-8 disclosures by reference and lists governing plan documents and legal and audit consents as exhibits.
Silexion Therapeutics Corp has furnished updated audited financial statements covering the year ended
FAQ
What is the current stock price of Silexion Therapeutics (SLXN)?
What is the market cap of Silexion Therapeutics (SLXN)?
